...Inc. (NASDAQ:FENC; TSX:FRX) received a complete response letter from FDA for its NDA for Pedmark sodium thiosulfate...
...3BCMA (TNFRSF17; CD269) – Tumor necrosis factor receptor superfamily member 17OX40L (CD134L) – OX40 ligand BC Staff STS, sodium thiosulfate...

...and granted Priority Review to an NDA from Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:FRX) for Pedmark sodium thiosulfate...

...Phase III SIOPEL 6 trial in 99 children receiving platinum-based chemotherapies showing that Pedmark (STS, sodium thiosulfate...
...NASDAQ:FENC), Research Triangle Park, N.C. Product: Pedmark (STS, sodium thiosulfate) Business: Otologic Molecular target: NA Description: Sodium thiosulfate...
...patients carrying or not carrying 2 key gene mutations Status: Phase III data Milestone: NA Claire Quang sodium thiosulfate Fennec...

...$4 in a private placement to Essetifin and venBio Select Advisor and other investors. Fennec’s sodium thiosulfate...

...anterior uveitis Ph III data; submit NDA 1Q17; late 2017 Fennec Pharmaceuticals Inc. (TSX:FRX; OTCQB:FENCF) Sodium thiosulfate...

...companies have disclosed compounds for congenital forms of hearing loss. Fennec Pharmaceuticals Inc. (TSX:FRX; OTCQB:FENCF) Sodium thiosulfate...

...OTCQB:FENCF), Research Triangle Park, N.C. Product: Sodium thiosulfate (STS) Business: Other Molecular target: Not available Description: Sodium thiosulfate...

...are developing treatments to preserve hearing during chemotherapy. Fennec Pharmaceuticals Inc. has the small molecule sodium thiosulfate...

...OTCQB:FENCF), Research Triangle Park, N.C. Product: Sodium thiosulfate (STS) Business: Other Molecular target: Not available Description: Sodium thiosulfate...

...other companies have therapeutics in development to prevent chemotherapy-induced hearing loss. Fennec Pharmaceuticals Inc. 's sodium thiosulfate...